+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Intracranial Hypertension Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023 - Product Image

Idiopathic Intracranial Hypertension Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

  • ID: 4856405
  • Report
  • October 2019
  • Region: Global
  • 153 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
Global Idiopathic Intracranial Hypertension Therapeutics Market: About this market
The idiopathic intracranial hypertension market analysis considers sales from carbonic anhydrase inhibitors and other drug classes products. Our study also finds the sales of idiopathic intracranial hypertension in Asia, Europe, North America, and ROW. In 2018, the carbonic anhydrase inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as improved vision and decreased intracranial pressure and papilledema will play a significant role in the carbonic anhydrase inhibitors segment to maintain its market position. Also, our global idiopathic intracranial hypertension market report looks at factors such as rising incidences of idiopathic intracranial hypertension, increasing morbidity and mortality rates associated with heart diseases, and identification of risk factors associated with idiopathic intracranial hypertension. However, the asymptomatic nature of disease, limited patient pool, side effects associated with idiopathic intracranial hypertension therapeutics may hamper the growth of the idiopathic intracranial hypertension industry over the forecast period.

Global Idiopathic Intracranial Hypertension Therapeutics Market: Overview

Rising incidences of idiopathic intracranial hypertension
Developed economies such as the US and other countries are witnessing a high incidence of obesity and cardiovascular disorders, which has increased the patient pool for idiopathic intracranial hypertension. This has increased the need for immediate therapeutic interventions such as idiopathic intracranial hypertension therapeutics. Thus, the rising incidence of idiopathic intracranial hypertension will lead to the expansion of the global milk chocolate market at a CAGR of almost 3% during the forecast period.

Increasing number of awareness campaigns.
The global idiopathic intracranial hypertension therapeutics market is expected to benefit from the increasing number of awareness activities that are being undertaken by public and private organizations across the world. For instance, IIH UK, a forum managed by Rare Disease Europe (EURORDIS), helps patients with idiopathic intracranial hypertension in managing their condition. EURORDIS helps increase awareness about rare diseases and focuses on improving the health of patients with rare diseases. The organization conducts specialized social services and facilitates R&D and healthcare policies. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of a few major players, the global idiopathic intracranial hypertension market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading idiopathic intracranial hypertension manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the idiopathic intracranial hypertension market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Carbonic anhydrase inhibitors - Market size and forecast 2018-2023
  • Other drug classes - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing number of awareness campaigns
  • Rising incidence of rare diseases
  • Special drug designations
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Carbonic anhydrase inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Carbonic anhydrase inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 22: Other drug classes - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other drug classes - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Adoption rate of health insurance coverage among US adults with CHD and/or stroke (2019)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie Inc. - Vendor overview
Exhibit 50: AbbVie Inc. - Business segments
Exhibit 51: AbbVie Inc. - Organizational developments
Exhibit 52: AbbVie Inc. - Geographic focus
Exhibit 53: AbbVie Inc. - Key offerings
Exhibit 54: AbbVie Inc. - Key customers
Exhibit 55: Astellas Pharma Inc. - Vendor overview
Exhibit 56: Astellas Pharma Inc. - Business segments
Exhibit 57: Astellas Pharma Inc. - Organizational developments
Exhibit 58: Astellas Pharma Inc. - Geographic focus
Exhibit 59: Astellas Pharma Inc. - Key offerings
Exhibit 60: Astellas Pharma Inc. - Key customers
Exhibit 61: Cadila Healthcare Ltd. - Vendor overview
Exhibit 62: Cadila Healthcare Ltd. - Product segments
Exhibit 63: Cadila Healthcare Ltd. - Organizational developments
Exhibit 64: Cadila Healthcare Ltd. - Geographic focus
Exhibit 65: Cadila Healthcare Ltd. - Key offerings
Exhibit 66: Cadila Healthcare Ltd. - Key customers
Exhibit 67: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 68: Johnson & Johnson Services Inc. - Business segments
Exhibit 69: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 70: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 71: Johnson & Johnson Services Inc. - Segment focus
Exhibit 72: Johnson & Johnson Services Inc. - Key offerings
Exhibit 73: Johnson & Johnson Services Inc. - Key customers
Exhibit 74: Merck & Co. Inc. - Vendor overview
Exhibit 75: Merck & Co. Inc. - Business segments
Exhibit 76: Merck & Co. Inc. - Organizational developments
Exhibit 77: Merck & Co. Inc. - Geographic focus
Exhibit 78: Merck & Co. Inc. - Segment focus
Exhibit 79: Merck & Co. Inc. - Key offerings
Exhibit 80: Merck & Co. Inc. - Key customers
Exhibit 81: Mylan NV - Vendor overview
Exhibit 82: Mylan NV - Product segments
Exhibit 83: Mylan NV - Organizational developments
Exhibit 84: Mylan NV - Geographic focus
Exhibit 85: Mylan NV - Segment focus
Exhibit 86: Mylan NV - Key offerings
Exhibit 87: Mylan NV - Key customers
Exhibit 88: Pfizer Inc. - Vendor overview
Exhibit 89: Pfizer Inc. - Business segments
Exhibit 90: Pfizer Inc. - Organizational developments
Exhibit 91: Pfizer Inc. - Geographic focus
Exhibit 92: Pfizer Inc. - Segment focus
Exhibit 93: Pfizer Inc. - Key offerings
Exhibit 94: Pfizer Inc. - Key customers
Exhibit 95: Sanofi - Vendor overview
Exhibit 96: Sanofi - Business segments
Exhibit 97: Sanofi - Organizational developments
Exhibit 98: Sanofi - Geographic focus
Exhibit 99: Sanofi - Segment focus
Exhibit 100: Sanofi - Key offerings
Exhibit 101: Sanofi - Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • MORE
The following companies as the key players in the global idiopathic intracranial hypertension Therapeutics market: AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing number of awareness campaigns.”

According to the report, one of the major drivers for this market is the rising incidences of idiopathic intracranial hypertension.

Further, the report states that one of the major factors hindering the growth of this market is the asymptomatic nature of the disease.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Cadila Healthcare Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll